EPHA1 and cancer: A combined strategy that targets the binding between more than one Eph receptor to the respective ligands has been suggested as a therapy in cancer, and a pan-Eph compound that inhibits binding of Ephs to ephrins has already been synthesised and has given positive results when tested in models of glioblastoma29.